Home - Products - Angiogenesis - JAK - Pumecitinib

Pumecitinib

CAS No. 2401057-12-1

Pumecitinib( —— )

Catalog No. M35964 CAS No. 2401057-12-1

Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	50	In Stock
5MG	42	In Stock
10MG	67	In Stock
25MG	124	In Stock
50MG	193	In Stock
100MG	275	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Pumecitinib
Note

Research use only, not for human use.
Brief Description

Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
Description

Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

JAK
Recptor

JAK
Research Area

——
Indication

——

Chemical Information

CAS Number

2401057-12-1
Formula Weight

400.46
Molecular Formula

C17H20N8O2S
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 125 mg/mL (312.14 mM; Ultrasonic (<60°C)
SMILES

CC(C)S(=O)(=O)N1CC(CC#N)(C1)n1cc(c(N)n1)-c1ncnc2[nH]ccc12
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. WHO Drug Information-World Health Organization (WHO).

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

BT-11

BT-11 is an orally available LANCL2 binding compound. It is used in the therapy of inflammatory bowel disease.
CEP-33779

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
ZT55

ZT55 (JAK inhibitor ZT55) is a novel potent, highly-selective tyrosine kinase JAK2 inhibitor with IC50 of 31 nM.

Sign In Join Free